TY - JOUR
T1 - Comparison of effects of chronic administration of naloxone and naloxonazine upon food intake and maintainance of body weight in rats
AU - Mann, Phyllis E.
AU - Pasternak, G. W.
AU - Hahn, E. F.
AU - Curreri, Geneveive
AU - Lubin, E.
AU - Bodnar, R. J.
PY - 1988/4
Y1 - 1988/4
N2 - A comparison of the effects of the short-acting opioid antagonist naloxone, with the irreversible and highly-specific mu-1 antagonist naloxonazine, has categorized the mediation of opioids in some forms of feeding into mu-1 and non-mu-1 components. The mu-1 sites have been implicated in free-feeding, deprivation-induced feeding and morphine-induced hyperphagia, based upon their sensitivity to both naloxone and naloxonazine. However, the ability of naloxone, but not naloxonazine to inhibit feeding, induced by either 2-deoxy-d-glucose glucoprivation, ethylketocyclazocine, dynorphin or (d-ala2., d-leu5.)-enkephalin implies the existence of non-mu-1 opioid receptor mechanisms in these responses. The present study compared the effects of the daily administration of naloxone and naloxonazine (10 mg/kg, i.v.) in rats in three different types of maturational or dietary situations. In adult rats, naloxonazine and naloxone significantly reduced body weight (7% and 4%, respectively) and food intake (21% and 13%, respectively) over 14 days. These effects were more pronounced in adolescent rats where naloxonazine and naloxone significantly reduced the gain in body-weight (53% and 33%, respectively) and food intake (24% and 15%, respectively) over 14 days. In the adolescent rats, the effects of naloxonazine were significantly greater than those of naloxone. In contrast, chronic treatment with neither naloxone nor naloxonazine altered body weight or food intake of rats made obese by dietary manipulations and left on that diet during treatment with an antagonist. These data indicate that chronic blockade of mu-1 receptors decreased body weight and food intake in normal adult and adolescent rats for at least 2 weeks. However, development and maintainance of dietary obesity appeared to override the chronic effects of treatment with an opiate antagonist.
AB - A comparison of the effects of the short-acting opioid antagonist naloxone, with the irreversible and highly-specific mu-1 antagonist naloxonazine, has categorized the mediation of opioids in some forms of feeding into mu-1 and non-mu-1 components. The mu-1 sites have been implicated in free-feeding, deprivation-induced feeding and morphine-induced hyperphagia, based upon their sensitivity to both naloxone and naloxonazine. However, the ability of naloxone, but not naloxonazine to inhibit feeding, induced by either 2-deoxy-d-glucose glucoprivation, ethylketocyclazocine, dynorphin or (d-ala2., d-leu5.)-enkephalin implies the existence of non-mu-1 opioid receptor mechanisms in these responses. The present study compared the effects of the daily administration of naloxone and naloxonazine (10 mg/kg, i.v.) in rats in three different types of maturational or dietary situations. In adult rats, naloxonazine and naloxone significantly reduced body weight (7% and 4%, respectively) and food intake (21% and 13%, respectively) over 14 days. These effects were more pronounced in adolescent rats where naloxonazine and naloxone significantly reduced the gain in body-weight (53% and 33%, respectively) and food intake (24% and 15%, respectively) over 14 days. In the adolescent rats, the effects of naloxonazine were significantly greater than those of naloxone. In contrast, chronic treatment with neither naloxone nor naloxonazine altered body weight or food intake of rats made obese by dietary manipulations and left on that diet during treatment with an antagonist. These data indicate that chronic blockade of mu-1 receptors decreased body weight and food intake in normal adult and adolescent rats for at least 2 weeks. However, development and maintainance of dietary obesity appeared to override the chronic effects of treatment with an opiate antagonist.
KW - body weight regulation
KW - dietary obesity
KW - food intake
KW - mu-1 opiate binding site
KW - naloxonazine
KW - naloxone
UR - http://www.scopus.com/inward/record.url?scp=0023902701&partnerID=8YFLogxK
U2 - 10.1016/0028-3908(88)90142-6
DO - 10.1016/0028-3908(88)90142-6
M3 - Article
C2 - 3419536
AN - SCOPUS:0023902701
SN - 0028-3908
VL - 27
SP - 349
EP - 355
JO - Neuropharmacology
JF - Neuropharmacology
IS - 4
ER -